Roche announces FDA approves Susvimo to treat DME

Roche (RHHBY) announced that the Food and Drug Administration has approved Susvimo 100 mg/mL for the treatment of diabetic macular edema, a leading cause of vision loss in adults with diabetes. “Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME with fewer treatments than standard-of-care eye injections.4-6 Susvimo is now available to US retina specialists and their patients with DME,” the company stated. “Susvimo presents a unique, convenient treatment alternative to routine eye injections for people with a potentially blinding diabetic eye condition,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “As the global prevalence of diabetic macular edema continues to grow, today’s FDA approval for Susvimo reflects our dedication to innovation and enhancing the patient experience.”